Kevzara
Chemical Name | sarilumab |
Dosage Form | Injection (subcutaneous; 150 mg/1.14 mL, 200 mg/1.14 mL) |
Drug Class | Monoclonal antibodies |
System | Musculoskeletal |
Company | Sanofi-Aventis |
Approval Year | 2017 |
Indication
- For treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs